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Abstract 
Obesity and overweight are two of the most health challenges with an increasing 
prevalence in recent years, in which several complications have been identified to have a 
high impact in patients’ health conditions. In this vein, an increasing interest in the gut 
microbiota has emerged as a target for therapeutic strategies in obesity and overweight 
due to its direct relation with the aforementioned health conditions and complications. 
Thus, the aim of this study was to evaluate the efficacy of probiotics as a therapeutic 
strategy in the management of obesity and overweight. A systematic review of 
randomized controlled trials was carried out in 6 databases until May 2019 to assess the 
use of probiotics in obesity and overweight patients. The Jadad Scale was used to assess 
the quality of clinical trials. Twenty-three clinical trials published between 2000 and 2019 
met the inclusion criteria. The role of probiotics in reducing body mass index and weight 
as well as changing the visceral abdominal fat area, waist and hip circumference were 
shown in 14 of 23 trials (60.87%); 14 trials (60.87%) showed changes on patients’ fatty 
acids and biomarkers; and 4 trials (17.39%) studied the role of the gut microbiota in obese 
and overweight patients. Some probiotics strains are shown to be effective in reducing 
body mass index and hip circumference. This review provides evidence of successful 
results in weight loss using probiotic groups.  
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Two of the most important health challenges worldwide are obesity and overweight, 
which also constitute a global risk for mortality. In this matter, 1.9 billion adults were 
overweight in 2016, of whom 650 million were obese (Bentham et al., 2017; Borgeraas 
et al., 2018; Hadi et al., 2018; WHO, 2018). Moreover, obesity and overweight have been 
shown to have several medical complications such as cardiovascular diseases, metabolic 
disorders, respiratory disorders, muscle-skeletal disorders and social and psychological 
alterations, among others and therefore, the increasing interest for their prevention and 
treatment acquire great importance between health professionals (Hadi et al., 2018; 
Hampl and Campbell, 2015; King and Ajjan, 2016; Rizzetto et al., 2018; Wang et al., 
2019). 
In recent years, the gut microbiota has been widely studied in nutrition for its implication 
in the pathophysiology for obesity and overweight (Gérard, 2016; Gomes et al., 2018; 
Maruvada et al., 2017; Turnbaugh et al., 2006). This implication has been shown to be 
related to its ability to modulate gastrointestinal (GI) functions such as intestinal motility 
(Fayfman et al., 2019) and permeability (Karl et al., 2017), mucosal immune function 
(Rizzetto et al., 2018), and activity in the enteric nervous system (Heiss and Olofsson, 
2019; Obata and Pachnis, 2016). Obesity is widely associated with a lower bacterial 
diversity and an increased Firmicutes/Bacteroidetes ratio, an event known as intestinal 
dysbiosis (Gomes et al., 2018). It is worth noting that both, a recent systematic review 
(Crovesy et al., 2020) and a meta-analysis (Mitev and Taleski, 2019), corroborate this 
imbalance Firmicutes/Bacteroidetes ratio in obese individuals, pointing to a different 
microbiota profile for individuals with obesity, which decreases if the person loses 
weight. 
In this context, intestinal bacteria species are key in the synthesis of short-chain fatty acids 
(SCFA) by decreasing inflammation (Zhai et al., 2019), intervening in the degradation of 
complex carbohydrates (Flint et al., 2012) and transforming primary bile acids into 
secondary ones, which are fundamental for the emulsification, degradation and absorption 
of cholesterol, fats and fat-soluble vitamins (Ramírez-Pérez et al., 2017). 
The gut microbiota can be modulated by different ways, such as diet, faecal microbial 
transplantation (de Groot et al., 2017; Paramsothy et al., 2017), drugs, especially 
antibiotics (Becattini et al., 2016; Ianiro et al., 2016; Noh et al., 2017), as well as 
probiotics, prebiotics and symbiotics (Ferrarese et al., 2018). In this sense, probiotics 
have been defined as living organisms that consumed in adequate amounts provide 
beneficial health effects (FAO/WHO, 2001). These probiotics and other gut microbiota 
modulators may alter the secretion of hormones, neurotransmitters, and inflammatory 
factors, and therefore preventing food intake triggers that lead to weight gain (Aoun et 
al., 2020). Experimental studies have shown anti-obesogenic effects after probiotics 
treatments, mainly  Lactobacillus and Bifidobacterium, characterized by a lower weight 
gain as well as a reduction on fat accumulation (Ejtahed et al., 2019). Some of the 
mechanisms of action proposed include induction in fatty acid oxidation genes or 
regulation of the genes involved in lipid metabolism (Dahiya et al., 2017). In addition, 
some strains of Lactobacilli can produce bacteriocins, antimicrobial peptides that are 
related with body weight. Moreover, probiotics prevent dysbiosis and protect the 
intestinal barrier through the modulation of cytoskeletal (Cerdó et al., 2019). Another 
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mechanism of action postulated is related to their ability to compete with microorganisms 
for binding sites by antagonizing these pathogens or by modulating the recipients’ 
immune response. There are several microorganisms recognized as probiotics and not all 
of them have the same effects and mechanisms of action, and thereby further discussion 
using probiotics as a therapeutic strategy is needed (Hadi et al., 2018; Sanchis-Chordà et 
al., 2018; Sarao and Arora, 2017). Thus, the aim of this study was to evaluate the efficacy 
of probiotics as a therapeutic strategy in the management of obesity and overweight in 




In May 2019, a systematic review of clinical trials was conducted. The review process 
followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyzes 
(PRISMA) statement (Moher et al., 2009). A structured Patient-Intervention-Outcomes 
(PIO) question was planned as follows (Stone, 2002): Does probiotics constitute an 
effective therapeutic strategy in obese or overweight patients? 
This study was carried out in main health science databases: PubMed, Cochrane Library, 
ProQuest, CINAHL, Science Direct and Scopus; combining natural language and 
structured language, using the following MeSH terms: “probiotics”, “microbiota”, 
“obesity” and “overweight”. The search strategy used was adapted to each database (see 
Supplement File 1). The only filter used was “clinical trials” as article type in PubMed. 
 
Selection criteria 
The following inclusion criteria were used: (i) randomized clinical trials, (ii) papers 
related to the aim of the study; evaluate the efficacy of probiotics as a therapeutic strategy 
in the management of loss weight, obesity and/or overweight, (iii) adults aged 18-65 
years, (iv) language of publication in English, (iv) included at least one of the following 
variables: BMI and change in weight, and (v) studies with at least a probiotic intervention. 
The exclusion criteria were: (i) studies conducted in patients with HIV, cancer, diabetes, 
cardiovascular diseases, pregnant women, and breastfeeding, (ii) re-publications, and (iii) 
studies within animals.  
Screening of studies 
The eligibility of studies was done in three phases. The first phase consisted in reading 
the title of articles identified throughout the database searching. Once selected, all 
abstracts were reviewed in a second phase. And finally, full-text reading was used when 
needed for clarification and in order to discern the suitability of selecting the paper for its 
analysis. The eligibility process was done by the two first authors (MRA, XM) 
independently and in duplicate, if consensus could not be achieved, a third author (PR) 
was consulted. In relation to the included studies, a bibliometric analysis was carried out 
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on the following variables: (i) methods, (ii) participants, (iii) criteria of the studies, (iv) 
duration of the intervention, (v) probiotics strains used and (vi) results.  
 
Quality of evidence 
Besides, a critical reading analysis was performed with the Jadad Scale of Clinical Trials 
to assess the methodological quality of the analysed studies. This is a scale with five 
simple items and it has known reliability and external validity. A score below 3 points 
indicates low quality based on the quality of randomization, double blinding, and drop-
outs extracted of each study (Jadad et al., 1996). Any discrepancy was discussed by 




Combining the aforementioned terms resulted in 586 articles [PubMed (n=105), 
Cochrane Library (n=154), Proquest (n=97), CINAHL (n=98), Science Direct (n=62), 
and Scopus (n=70)], from which 345 were discarded by duplicity. From the 241 
remaining documents, 218 were excluded according to our selection criteria. And finally, 
a total of 23 documents were included in this systematic review for their analysis. The 
review and selection processes are detailed in Figure 1. 
[INSERT FIGURE 1 AROUND HERE] 
 
Literature characteristics of included studies 
Trials and patients’ characteristics are compiled in Table 1. Overall, participants in most 
of the 23 analysed articles were obese and overweight volunteers, except for five studies 
(Bernini et al., 2016; Hulston et al., 2015; Leber et al., 2012; Ogawa et al., 2014; 
Osterberg et al., 2015). In three trials (Bernini et al., 2016; Chung et al., 2016; Zarrati et 
al., 2013), the gender of participants was not specified and only women participated in 
Lee and collaborators’ (2014) and Madjd and collaborators’ trials (2016), as well as only 
men participated in the study of Osterberg and collaborators’ (2015). Inclusion criteria 
involved an age between 18 and 75 years old (mean age 44.1 years old), enrolling a total 
of 1996 patients. All manuscripts were published between 2000 and 2019, and 12 clinical 
trials (52.17%) were not registered in a clinical trial registry. Most of the studies were 
performed in Asia (n=13), Europe (n=6), America (n=3) and only one was from Oceania 
(n=1). 12 studies (52.17%) included participants who consumed a single strain of 
probiotics, and 11 studies (47.83%) included participants who consumed two or multiple 
strains of probiotics. Also, probiotics were administered in different forms and duration 
of the probiotic supplementation ranged from 4 weeks to 6 months. One study evaluated 
the effects of probiotic in two different presentations (Ivey et al., 2014). The range dose 
was between 106 from 1012 CFU/day, although in two studies the dose in CFU was not 
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indicated (Hulston et al., 2015; Nakamura et al., 2016). Doses of the same probiotic are 
evaluated in two studies (Kadooka et al., 2013; Kim et al., 2018) and other two studies 
compared the effect between heat-killed or living strain (Higashikawa et al., 2016; Pedret 
et al., 2019). Nevertheless, it is noteworthy that two of the studies analysed evaluate also 
the effect of prebiotic and symbiotic (Hibberd et al., 2019; Stenman et al., 2016). 
Moreover, microbial composition changes were reported as outcomes only in 3 studies 
(13.04%). And finally, 16 studies (69.57%) reported positive results on different 
parameters (e.g. body weight, fat mass, BMI, biomarkers, etc.), whilst 7 studies (30.43%) 
reported no impact in their results. 
[INSERT TABLE 1 AROUND HERE] 
 
Effects of probiotics in weight and BMI 
The role of probiotics in reducing BMI and weight or changing the visceral abdominal fat 
area, waist and hip circumference was demonstrated in 12 of 23 trials (52.17%) (Bernini 
et al., 2016; Chung et al., 2016; Higashikawa et al., 2016; Kadooka et al., 2010, 2013; 
Kim et al., 2018; Lee et al., 2014; Nakamura et al., 2016; Osterberg et al., 2015; Pedret 
et al., 2019; Stenman et al., 2016; Takahashi et al., 2016). It is interesting to note that 9 
of these studies were performed in Asia where the population’s BMI is lower than in 
America or Europe (Castaner et al., 2018).  
The probiotics strains employed along these studies were: Bifidobacterium animalis 
subsp. lactis, subsp nov. HN019; Lactobacillus reuteri JBD301, Pediococcus 
pentosaceus LP28, Lactobacillus gasseri BNR17, Lactobacillus amylovorus CP1563, 
Bifidobacterium animalis spp. lactis BA8145, Bifidobacterium animalis spp. lactis B420, 
and Bifidobacterium lactis GCL2505. In other clinical trials, probiotics were used in 
combination (Streptococcus thermophilus and Lactobacillus delbrueckii ssp. bulgaricus, 
along with Lactobacillus gasseri LG2055), (Streptococcus thermophiles KCTC 
11870BP, Lactobacillus plantarum KCTC 107892BP, Lactobacillus acidophilus KCTC 
11906BP, Lactobacillus rhamnosus KCTC 12202BP, Bifidobacterium lactis KCTC 
11904BP, Lactobacillus longum KCTC 12200BP, and Bifidobacterium breve KCTC 
12201BP), (Streptococcus thermophilus DSM24731, and Lactobacillus acidophilus 
DSM24735). The treatment period varied from 4 weeks to 6 months, being the 12-week 
period the most commonly used. The effects of probiotic over gender were only indicated 
in the study of Pedret and collaborators (2019), where the probiotic effects were observed 
only in women. 
On the other hand, 7 trials (30.43%) indicated the poor efficacy of probiotics in reducing 
BMI, weight or other anthropometric parameters (Hibberd et al., 2019; Hulston et al., 
2015; Ivey et al., 2014; Jung et al., 2013; Leber et al., 2012; Lee et al., 2014; Madjd et 
al., 2016). Only in 3 studies (13.04%) the anthropometric measures were not reported as 
outcomes (Culpepper et al., 2019; Ogawa et al., 2014; Zarrati et al., 2014). The probiotics 
used in these studies included Lactobacillus gasseri BNR17, Treptococcus thermophiles, 
Lactobacillus bulgaricus, Bifidobacterium lactis BB, Lactobacillus acidophilus LA, 
Lactobacillus acidophilus La5, Bifidobacterium animalis subsp lactis BB12, 
Bifidobacterium subtilis R0179, Streptococcus thermophiles KCTC 11870BP, 
Lactobacillus plantarum KCTC 107892BP, Lactobacillus acidophilus KCTC 11906BP, 
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Lactobacillus rhamnosus KCTC 12202BP, Bifidobacterium lactis KCTC 11904BP, 
Lactobacillus longum KCTC 12200BP, and Bifidobacterium breve KCTC 12201BP. The 
treatment of these studies ranges from 4 weeks to 3 months. 
 
Effects of probiotics in other biomarkers 
In reference to the changes on patients’ fatty acids and biomarkers, a total of 13 trials 
(56.52%) showed changes (Agerholm-Larsen et al., 2000; Bernini et al., 2016; Hibberd 
et al., 2019; Hulston et al., 2015; Ivey et al., 2014; Kadooka et al., 2013; Madjd et al., 
2016; Nakamura et al., 2016; Ogawa et al., 2014; Pedret et al., 2019; Stenman et al., 
2016; Zarrati et al., 2013, 2014). In that sense, the literature reviewed showed an impact 
from probiotics treatments, where the improved metabolic health status was indicated as 
a decrease of total cholesterol, LDL, triglyceride concentration, and a reduction of 
esterified fatty acid (OFLT), non-esterified fatty acids (NEFA) and triacylglycerol 
(TAG). Indeed, there were reductions in total cholesterol, LDL, and an increase in the 
insulin resistance index (HOMA-IR) according to the study of Madjd and collaborators 
(2016). Likewise, the HOMA-IR was also reduced in Ivey and collaborators’ results 
(2014) and in Pedret and collaborators’ (2019). Nevertheless, it was not reported any 
reduction in total cholesterol, HDL, or triglycerides. On the other hand, a slight 
improvement was shown in Madjd and collaborators’ (2016) and Culpepper and 
collaborators’ findings (2019), but not significant enough to demonstrate the role of 
probiotics. Conversely, there were studies which showed negative effects correlated with 
endotoxin levels and total cholesterol, HDL, LDL and triglycerides, but there were no 
significant changes in their results (Jung et al., 2013; Lee et al., 2014). In the same 
manner, inconclusive results for changes in these biomarkers were reported in one study 
(Ivey et al., 2014).  
Conversely, impact on immune systems were also reported in 6 studies (Agerholm-Larsen 
et al., 2000; Bernini et al., 2016; Stenman et al., 2016; Zarrati et al., 2013, 2014). Five of 
these trials showed changes in levels of zonulin and CRP, a reduction of leptin levels as 
well as a stimulation of the IL-10 production and therefore an inhibition of TH1 and its 
cytokines. Concerning to the impact on the gut microbiota, three studies (13.04%) 
evaluated that relationship between fatty acids reduction and probiotics. Stenman et al. 
(2016) observed an increase of the concentration of faecal propionic acid, butyric acid 
and valeric acid, as well as total faecal SCFA concentrations. However, no significant 
changes in SCFA, amino acids were noticed by Hibberd and collaborators (2019) and 
Pedret and collaborators (2019). In the same line, four studies (17.39%) assessed the 
effects of probiotics treatments over gut microbiota, which found an increase of bacterial 
composition. In that sense, Pedret and collaborators (2019) identified an increase in 
Akkermansia spp. after 3 months of treatment with Bifidobacterium animalis spp. lactis. 
Takahashi and collaborators (2016) observed an increased number of faecal 
bifidobacterial after 12 weeks of treatment with Bifidobacterium lactis GCL2505. Lee 
and collaborators (2014) noticed an increase of the levels of B. breve, B. lactis, and L. 
rhamnosus after the treatment with a probiotic multispecies during 6 weeks. And finally, 
Osterberg and collaborators (2015) detected greater faecal bacterial enrichment in groups 
treated with a probiotic multispecies during 4 weeks. 
 




The average quality of the analysed studies scored 3.52 in the Jadad Scale (Table 2). Its 
variability was ranged from 2 (in four studies), 3 (in eight studies), 4 (in six studies) to 5 
(in five studies), and none had an unacceptable reporting quality (lower than 1). As for 
potential sources of sponsorship bias, 8 analysed studies received funding from different 
manufacturers (Bernini et al., 2016; Chung et al., 2016; Hibberd et al., 2019; Hulston et 
al., 2015; Lee et al., 2014; Nakamura et al., 2016; Ogawa et al., 2014; Takahashi et al., 
2016).  
[INSERT TABLE 2 AROUND HERE] 
 
4. Discussion 
The aim of the present study was to evaluate the efficacy of probiotics as a therapeutic 
strategy against obesity and overweight on humans. In this sense, this systematic review 
from 23 randomized controlled trials showed the beneficial effects that probiotics may 
have in obesity and overweight management. That is, a reduction in BMI and weight 
among other anthropometric measures, which were observed in 12 of 23 trials (52.17%); 
along with 14 trials (60.87%) that showed changes on patients’ fatty acids and other 
biomarkers. Our results are according to other found in previous reviews about the topic 
(Azad et al., 2018; Borgeraas et al., 2018; Rouxinol-Dias et al., 2016; Wang et al., 2019). 
There exists a wide variety of strains which can be used in order to obtain these beneficial 
health effects. Thus, Streptococcus thermophilus strain was the most widely used (Bernini 
et al., 2016; Kadooka et al., 2013; Lee et al., 2014; Osterberg et al., 2015; Zarrati et al., 
2014). Almost half of the reviewed manuscripts employed a multi-strain probiotics 
(Agerholm-Larsen et al., 2000; Culpepper et al., 2019; Ivey et al., 2014; Kadooka et al., 
2010, 2013; Lee et al., 2014; Madjd et al., 2016; Ogawa et al., 2014; Osterberg et al., 
2015; Zarrati et al., 2013, 2014), which seems to be more effective than a single strain 
according to a recent meta-analysis (Koutnikova et al., 2019). Regarding the duration of 
the intervention, the most common treatment was 12 weeks, that seems to be enough to 
demonstrate changes in body weight. Others authors, such as Bernini and collaborators 
(2016), Madjd and collaborators (2016), or Ogawa and collaborators (2014), among 
others, used Lactobacillus bulgaricus strain with similar significant results in a length of 
time alike. Many authors (Agerholm-Larsen et al., 2000; Chung et al., 2016; Higashikawa 
et al., 2016; Kadooka et al., 2010; Kim et al., 2018) agree in the positive effects of 
probiotics for changing metric parameters like weight and BMI, particularly in the 
abdominal region, waist and hip circumference, diastolic blood pressure, fat percentage, 
whole body fat, and visceral fat. In this sense, Pedret and collaborators’ results (2019) 
demonstrated how the consumption of probiotics such as BA8145 improves biomarkers 
of anthropometric adiposity such as visceral fat area, BMI, waist circumference, waist-
to-hip ratio and conicity index, particularly in women, and appears to constitute a 
complementary strategy in obesity. 
Regarding to the effects of probiotics in other biomarker measures, Stenman and 
collaborators’ (2016), and Zarrati and collaborators’ results (2014) among others revealed 
how this process induced changes at protein levels like levels of zonulin and CRP, besides 
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immunology and metabolic changes. For that matter, Ogawa and collaborators (2014) 
showed how levels of post-nephric NEFA and levels of TAG in the active fermented milk 
(FM) period were lower (p <0.005) than in the FM control group.  
New probiotics such as Akkermansia muciniphila have a negative correlation with 
overweight and obesity (Vallianou et al., 2020).  Results from both preclinical and clinical 
research have showed declined abundance of A. muciniphila in obesity and metabolic 
syndromes (Xu et al., 2020). This probiotic has been effective to improved metabolic 
biomarkers like insulin sensitivity, total cholesterol and also decrease inflammation 
(Depommier et al., 2019; Li et al., 2016). The role of A. muciniphila in body metabolism 
revealed to be a great option treatment of metabolic disorders associated with obesity. In 
fact, A. muciniphila impacts on SCFA production, which can have effects on glucose and 
lipid homeostasis (Xu et al., 2020). 
In this matter, a recent review points out to three mechanism of probiotics action over 
obesity: antimicrobial activity, immunomodulation and reduction of permeability barrier 
(Abenavoli et al., 2019). Treatments with a mixture of probiotics have been shown 
effective to alter host inflammation, adipose tissue hormone levels, and intestinal 
microbial composition. In that sense, Al-Muzafar and Amin’s results (2017) showed that 
co-administrated with a high fat diet induced changes in intestinal microbiota, which 
reduced serum lipid profiles and inflammatory biomarkers. Furthermore, some studies 
indicate that certain bacterial strains are able to decrease the inflammatory environment 
associated with gastrointestinal dysfunction in animal models of obesity and obese 
patients, whereas others find changes in levels of certain proteins involved in the energy 
balance (Park et al., 2019; Sun et al., 2020; Zarrati et al., 2013).  
One possible mechanism of action of probiotics over obesity could be their impact on 
cytokines induction (Maldonado-Galdeano et al., 2019). Thereby, Zarrati and 
collaborators (2013) showed that probiotics (Lactobacillus acidophilus LA5, 
Bifidobacterium BB12 and Lactobacillus casei DN001) also stimulate the production of 
IL-10 and therefore inhibit TH1 and its cytokines in an 8-week period. As these probiotics 
can also modify lipid and glucidic homeostasis, mRNA levels of peroxisome proliferator-
activated receptor-gamma (PPAR-γ) and PGC-1α, proteins that interact with PPAR-γ 
were significantly elevated, promoting the interaction of both and improving obesity in 
HFD mice after the administration of L. amylovorus KU4 (Park et al., 2019).  
In this sense, treatments with L. plantarum CGMCC1.557, L. fermentum CGMCC1.1880, 
B. breve CICC 6182 and L.casei CRL 431 showed an improvement in the composition of 
the intestinal bacteria, along with reduced levels of IL-1β, IL-6, IL-17, TNF-α and LPS 
and increased levels of IL-10, which had anti-inflammatory properties in mice fed with 
high-fat diets (HFD mice) and E.coli-induced endotoxemia (Novotny-Núñez et al., 2015; 
Sun et al., 2020). Similarly, a probiotic mixture containing B. animalis VLK and VKB 
and L. casei IMV B-7280 increased the levels of IL-4, IL- 10 and TGF- β in rats with 
monosodium glutamate-induced obesity (Falalyeyeva et al., 2017). In this vein, L. 
plantarum was shown as a promising strain for the reduction of hypercholesterolemia and 
adipogenesis in vitro experiments (Huang et al., 2019).  
In spite of the consistency among the reviewed trials, discrepancies in strain differences 
and individuals’ genotype were found. So, both Hulston and collaborators (2015), Leber 
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and collaborators (2012), as well as Madjd and collaborators (2016) showed poor effects 
of probiotics over anthropometric parameters. In the same line, a recent metanalysis 
showed that oral probiotics and/or symbiotic administration have no effect on body 
weight or BMI, although reduced minimally waist circumference (Suzumura et al., 2019). 
However, there are only two studies that did not find different effects between control 
and probiotics groups (Jung et al., 2013; Lee et al., 2014). That aside, despite there were 
no significant changes in body weight (Lee et al., 2014) and total cholesterol, HDL, LDL 
and triglycerides levels (Jung et al., 2013), an increase in bacteria composition was 
observed.  
It is interesting to note that the form of the probiotic has been also compared in some of 
the studies reviewed. Ivey and collaborators (2014) found that probiotic yogurt (PY) 
increased the HOMA-IR and fasting glucose concentration whilst the probiotic capsules 
did not. Also, heat-killed strain seems to be more effective than live strain (Higashikawa 
et al., 2016; Pedret et al., 2019).  
On the other hand, dietary interventions have been evaluated in two studies (Madjd et al., 
2016; Osterberg et al., 2015). Relevant results were obtained from Osterberg and 
collaborators (2015) who observed that a multispecies probiotic reduced the increase in 
body weight caused by a high-fat diet. The relationship between gut microbiota, obesity, 
diet and other factors such as physical exercise has been reviewed (Brahe et al., 2016). In 
fact, an increase of intestinal bacteria was detected in those patients who experienced 
weight loss through diet and exercise. As Hadi and collaborators’ (2018), and Prados-Bo 
and collaborators’ results (2015) suggest, the effectiveness of lifestyle interventions in 
weight loss seems to be influenced by the composition of each individual’s microbiota. It 
is well-known that one of the main activities of the intestine bacteria is to break down 
substrates like dietary fibre. As result of this degradation, SCFA are produced, 
interplaying between diet, gut microbiota and host energy metabolism. SCFA exert 
multiple effects on host metabolism by acting on glucose and lipid metabolism in various 
tissues, notably in liver, adipose tissue and muscle in which they act on insulin signalling 
and even, with a key role in gut-brain axis (Hadi et al., 2018; Rizzetto et al., 2018). 
Regarding potential mechanism to explain the aforementioned effects, there is growing 
evidence that support a link between the gut microbiota, SCFAs and obesity (Wang et al., 
2019). Gut microbiota has been evaluated only in four studies, but all of them found an 
increase of bacterial diversity or richness or an increased abundance in certain species  
(Lee et al., 2014; Osterberg et al., 2015; Pedret et al., 2019; Takahashi et al., 2016). This 
bacterial richness will modify the production of SCFA and consequently will lead to 
beneficial metabolic impact. In that matter, only Stenman and collaborators’ results 
(2016) showed an increased in the concentration of faecal propionic acid, butyric acid 
and valeric acid, as well as total faecal SCFA concentrations, whilst no significant 
changes in SCFA were observed by Hibberd and collaborators (2019) and Pedret and 
collaborators (2019).  
Other systematics reviews and metanalysis have evaluated the effects of probiotics 
treatments in obesity (Aoun et al., 2020; Borgeraas et al., 2018; Cerdó et al., 2019; Dahiya 
et al., 2017; Ejtahed et al., 2019; Koutnikova et al., 2019; Suzumura et al., 2019). Their 
results are according to our systematic review, showing that probiotics consumption 
improves anthropometric parameters and BMI. However, the exact mechanism of action 
still needs to be elucidated as it seems to be specific for each probiotic species and strain. 
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Nevertheless, more studies are necessary according to López-Moreno and collaborators 
(2020), due to the high variability between studies and lack of standardized protocols. 
 
Limitations 
Nevertheless, there is a number of limitations to consider when interpreting the results of 
this review. First, the number of excluded studies has been noteworthy due to its low 
methodological quality. Indeed, twelve clinical trials were not registered, which may have 
a risk of reporting bias. Our findings are based on consistent trials, following Jadad Scale. 
In addition, differences on strains, length of interventions and population of the studies 
may constitute confounding factors, and thereby generalizations should be made with 
caution. Due to the limited number of studies included, the effects of probiotics treatments 
in the prevention and treatment of overweight and obesity still need more consistent work, 
specially to identify potential mechanisms of action. Lastly, a wider strategy was used, 
using both probiotic and microbiota as natural and structured terms, to include the use of 
specific genera as some authors refer to probiotics by the specific genus used in their 
studies. 
In summary, this study contributes to the existing literature proving the efficacy of 
probiotics as a therapeutic strategy against obesity and overweight on humans. Further 
research is needed with larger sample groups and length of interventions in order to 
confirm the beneficial effects of probiotics as a therapeutic strategy. 
 
5. Conclusions 
In conclusion, our findings showed that some probiotics strains (Streptococcus 
thermophilus, Lactobacillus bulgaricus, Lactobacillus acidophilus, among others) are a 
valid therapeutic strategy to use against obesity and overweight by modifying metric 
parameters and other biomarkers, especially when multi-strains rather than single strains 
are used. The beneficial variation among different strains has been similar and thereby, 
all of them may be considered as a possible strategy to regulate the gut microbiota, being 
a 12-week treatment the most widely used and effective. Furthermore, these probiotics 
have showed to be more effective in reducing BMI and hip circumference. Also, 
probiotics administration could produce a beneficial effect in many biomarkers, such as 
cholesterol, LDL, triglyceride concentration or in HOMA-IR. In this vein, the 
composition of each individual’s microbiota seems to have an influence in avoiding a 
body weight increase during dietary interventions, where multispecies probiotics have 
been shown to be effective. 
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